IMTX

NASDAQ 已收盘

Immatics

5.95 USD
▼-0.15-2.46%
盘后 5.94 -0.17%
2026-11-19
市值
$878.58M
市盈率
—
EPS
-1.93
股息率
—
52 周区间
5.83 – 12.41
成交量
986.47K
Beta
1.35
目标价
16.03
52W 低 5.8352W 高 12.41
价格走势

公司简介

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy produ...